Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has announced the launch of its ALISCA™-Breast1 Phase II trial (PUMA-ALI-1201; NCT06369285). The study will evaluate alisertib, in combination with endocrine therapy,…
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for its…
Vir Biotechnology, Inc. (NASDAQ:VIR) today revealed positive results from the SOLSTICE Phase 2 clinical trial evaluating its investigational combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta…
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) commended the American College of Rheumatology (ACR) for its newly released 2024 evidence-based guidelines on the screening, treatment, and management of lupus nephritis (LN). The…
RheaVita, a leader in controlled, continuous freeze-drying technology for biopharmaceuticals, has entered into a strategic partnership with IMA Life, a global leader in advanced aseptic pharmaceutical production solutions and one…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNA interference (RNAi) therapeutics, today announced positive new results from its ongoing Phase 1 clinical trial of nucresiran (formerly ALN-TTRsc04), an investigational…
Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG), a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, has released its financial results for the second quarter and six months ending…
Cardinal Health recently celebrated the grand opening of its new Scientific Services Chemistry Center in Mansfield, Massachusetts. This state-of-the-art, FDA-regulated laboratory spans nearly 26,000 square feet and is designed to…
Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe ischemic diseases, today announced that the first patient has been dosed in its investigator-sponsored…
Geron Corporation (Nasdaq: GERN), a biopharmaceutical leader focused on transforming the treatment of blood cancers, announced today the appointment of Joseph Eid, M.D., as Executive Vice President of Research and…
Cyrus Biotechnology, Inc., a Seattle-based biotech company leveraging a novel hybrid AI/screening platform for biologics discovery, will showcase its expertise in protein engineering and risk mitigation for therapeutics at the…